{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T05:36:34Z","timestamp":1782797794232,"version":"3.54.5"},"reference-count":53,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T00:00:00Z","timestamp":1647043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Japanese Society for the Promotion of Science Grants-in-Aid for Scientific Research"},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP21bk0104107"],"award-info":[{"award-number":["JP21bk0104107"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,3,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>We aimed to evaluate the efficacy and safety of haematopoietic stem cell transplantation (HSCT) in patients with systemic sclerosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A systematic literature review and meta-analysis were carried out. We compared survival outcomes using the Kaplan\u2013Meier method with patient-level data between HSCT and intravenous pulse cyclophosphamide. Additionally, the incidence rate of treatment-related deaths with HSCT was pooled using a random-effect model.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of the 2091 articles screened, 22 were included: 3 randomized controlled trials and 19 observational studies. HSCT studies showed significant improvement in the skin thickness score and lung function. Despite treatment-related deaths being higher in HSCT than in intravenous pulse cyclophosphamide, the Kaplan\u2013Meier analysis showed a high survival rate of 2\u2009years post-transplant (log-rank, P\u2009=\u20090.004). The pooled frequency of transplant-related death from 700 systemic sclerosis patients was 6.30% (95% confidence interval 4.21\u20138.38). However, the estimated frequency of treatment-related deaths has been reducing over the last decade.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>HSCT is an effective treatment for systemic sclerosis, but the optimal indications must be carefully determined by balancing the risks.<\/jats:p><\/jats:sec>","DOI":"10.1093\/mr\/roac026","type":"journal-article","created":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T13:02:30Z","timestamp":1647262950000},"page":"330-337","source":"Crossref","is-referenced-by-count":11,"title":["Benefits and risks of haematopoietic stem cell transplantation for systemic sclerosis: A systematic review and meta-analysis"],"prefix":"10.1093","volume":"33","author":[{"given":"Kana","family":"Higashitani","sequence":"first","affiliation":[{"name":"Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine , Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4965-9274","authenticated-orcid":false,"given":"Kaoru","family":"Takase-Minegishi","sequence":"additional","affiliation":[{"name":"Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine , Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryusuke","family":"Yoshimi","sequence":"additional","affiliation":[{"name":"Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine , Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9488-661X","authenticated-orcid":false,"given":"Yohei","family":"Kirino","sequence":"additional","affiliation":[{"name":"Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine , Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Hamada","sequence":"additional","affiliation":[{"name":"Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine , Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideto","family":"Nagai","sequence":"additional","affiliation":[{"name":"Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine , Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maki","family":"Hagihara","sequence":"additional","affiliation":[{"name":"Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine , Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine , Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6181-4284","authenticated-orcid":false,"given":"Ho","family":"Namkoong","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Keio University School of Medicine , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Horita","sequence":"additional","affiliation":[{"name":"Chemotherapy Center, Yokohama City University Hospital , Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Nakajima","sequence":"additional","affiliation":[{"name":"Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine , Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,3,12]]},"reference":[{"key":"2023030304341143400_","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1056\/NEJMra0806188","article-title":"Mechanisms of disease scleroderma","volume":"360","author":"Gabrielli","year":"2009","journal-title":"N Engl J Med"},{"key":"2023030304341143400_","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1002\/1529-0131(200011)43:11<2437::AID-ANR10>3.0.CO;2-U","article-title":"Severe organ involvement in systemic sclerosis with diffuse scleroderma","volume":"43","author":"Steen","year":"2000","journal-title":"Arthritis Rheum"},{"key":"2023030304341143400_","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1136\/ard.2009.114264","article-title":"Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database","volume":"69","author":"Tyndall","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2023030304341143400_","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1007\/s00296-017-3826-y","article-title":"Determinants of mortality in systemic sclerosis: a focused review","volume":"38","author":"Poudel","year":"2018","journal-title":"Rheumatol Int"},{"key":"2023030304341143400_","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","article-title":"Update of EULAR recommendations for the treatment of systemic sclerosis","volume":"76","author":"Kowal-Bielecka","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2023030304341143400_","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus placebo in scleroderma lung disease","volume":"354","author":"Tashkin","year":"2006","journal-title":"N Engl J Med"},{"key":"2023030304341143400_","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1002\/art.22204","article-title":"A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma","volume":"54","author":"Hoyles","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2023030304341143400_","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1002\/art.30438","article-title":"Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung disease","volume":"63","author":"Roth","year":"2011","journal-title":"Arthritis Rheum"},{"key":"2023030304341143400_","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1164\/rccm.200702-326OC","article-title":"Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease","volume":"176","author":"Tashkin","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"2023030304341143400_","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease: Scleroderma Lung Study II (SLS-II), a double-blind, parallel group, randomised controlled trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med"},{"key":"2023030304341143400_","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00296-019-04481-8","article-title":"Effect of mycophenolate mofetil (MMF) on systemic sclerosis-related interstitial lung disease with mildly impaired lung function: a double-blind, placebo-controlled, randomized trial","volume":"40","author":"Naidu","year":"2020","journal-title":"Rheumatol Int"},{"key":"2023030304341143400_","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1002\/art.40114","article-title":"Mycophenolate versus placebo for systemic sclerosis-related interstitial lung disease: an analysis of scleroderma lung studies I and II","volume":"69","author":"Volkmann","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2023030304341143400_","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/BOR.0000000000000172","article-title":"Systemic sclerosis\u2014a systematic review on therapeutic management from 2011\u20132014","volume":"27","author":"Young","year":"2015","journal-title":"Curr Opin Rheumatol"},{"key":"2023030304341143400_","doi-asserted-by":"crossref","first-page":"e489","DOI":"10.1016\/S2665-9913(21)00107-7","article-title":"Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial","volume":"3","author":"Ebata","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"2023030304341143400_","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1093\/rheumatology\/ker269","article-title":"Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies","volume":"51","author":"Elhai","year":"2012","journal-title":"Rheumatology"},{"key":"2023030304341143400_","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1182\/bloodadvances.2017010041","article-title":"Evolution, trends, outcomes, and economics of hematopoietic stem cell transplantation in severe autoimmune diseases","volume":"1","author":"Snowden","year":"2017","journal-title":"Blood Adv"},{"key":"2023030304341143400_","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1182\/blood-2015-06-649145","article-title":"Autologous stem cell transplantation aids autoimmune patients by functional renewal and TCR diversification of regulatory T cells","volume":"127","author":"Delemarre","year":"2016","journal-title":"Blood"},{"key":"2023030304341143400_","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/bmt.2013.202","article-title":"Peripheral blood regulatory T cells in patients with diffuse systemic sclerosis (SSc) before and after autologous hematopoietic SCT: a pilot study","volume":"49","author":"Baraut","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"2023030304341143400_","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.bbmt.2018.01.020","article-title":"Autologous hematopoietic stem cell transplantation for systemic sclerosis: a systematic review and meta-analysis","volume":"24","author":"Shouval","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"2023030304341143400_","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"key":"2023030304341143400_","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/art.1780230510","article-title":"Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American rheumatism association diagnostic and therapeutic criteria committee","volume":"23","author":"Subcommittee for scleroderma criteria of the American rheumatism association diagnostic and therapeutic criteria committee","year":"1980","journal-title":"Arthritis Rheum"},{"key":"2023030304341143400_","first-page":"2737","article-title":"2013 classification criteria for systemic sclerosis","volume":"65","author":"van den Hoogen","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2023030304341143400_","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (Updated September 2020)","author":"Higgins","year":"2020"},{"key":"2023030304341143400_","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"2023030304341143400_","first-page":"119","article-title":"Approximate is better than \u2018exact\u2019 for interval estimation of binomial proportions","volume":"52","author":"Agresti","year":"1998","journal-title":"Am Stat"},{"key":"2023030304341143400_","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1001\/jama.2014.6368","article-title":"Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial","volume":"311","author":"van Laar","year":"2014","journal-title":"JAMA"},{"key":"2023030304341143400_","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S0140-6736(11)60982-3","article-title":"Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial","volume":"378","author":"Burt","year":"2011","journal-title":"Lancet"},{"key":"2023030304341143400_","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1703327","article-title":"Myeloablative autologous stem-cell transplantation for severe scleroderma","volume":"378","author":"Sullivan","year":"2018","journal-title":"N Engl J Med"},{"key":"2023030304341143400_","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/bmt.2016.211","article-title":"Autologous hematopoietic stem cell transplantation has better outcomes than conventional therapies in patients with rapidly progressive systemic sclerosis","volume":"52","author":"Papa","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"2023030304341143400_","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3899\/jrheum.110868","article-title":"Optimization of autologous stem cell transplantation for systemic sclerosis \u2014 a single-center longterm experience in 26 patients with severe organ manifestations","volume":"39","author":"Henes","year":"2012","journal-title":"J Rheumatol"},{"key":"2023030304341143400_","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41409-020-0978-2","article-title":"Cardiac safe hematopoietic stem cell transplantation for systemic sclerosis with poor cardiac function: a pilot safety study that decreases neutropenic interval to 5 days","volume":"56","author":"Burt","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"2023030304341143400_","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1136\/ard.2003.011205","article-title":"Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT\/EULAR registry","volume":"63","author":"Farge","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"2023030304341143400_","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1093\/rheumatology\/ket464","article-title":"Autologous stem cell transplantation with thiotepa-based conditioning in patients with systemic sclerosis and cardiac manifestations","volume":"53","author":"Henes","year":"2014","journal-title":"Rheumatology"},{"key":"2023030304341143400_","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1007\/s10067-019-04435-2","article-title":"Autologous haematopoietic stem cell transplantation (AHSCT) in autoimmune disease adult patients in France: analysis of the long-term outcome from the French Society for Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)","volume":"38","author":"Guillaume-Jugnot","year":"2019","journal-title":"Clin Rheumatol"},{"key":"2023030304341143400_","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-020-02255-3","article-title":"Low B cell counts as risk factor for infectious complications in systemic sclerosis after autologous hematopoietic stem cell transplantation","volume":"22","author":"Gernert","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"2023030304341143400_","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1007\/s10067-017-3954-5","article-title":"Safety profile of autologous hematopoietic stem cell mobilization and transplantation in patients with systemic sclerosis","volume":"37","author":"Helbig","year":"2018","journal-title":"Clin Rheumatol"},{"key":"2023030304341143400_","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/S0140-6736(12)62114-X","article-title":"Cardiac involvement and treatment-related mortality after non-myeloablative haemopoietic stem-cell transplantation with unselected autologous peripheral blood for patients with systemic sclerosis: a retrospective analysis","volume":"381","author":"Burt","year":"2013","journal-title":"Lancet"},{"key":"2023030304341143400_","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1136\/annrheumdis-2020-217058","article-title":"Predictive factors for treatment-related mortality and major adverse events after autologous haematopoietic stem cell transplantation for systemic sclerosis: results of a long-term follow-up multicentre study","volume":"79","author":"van Bijnen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2023030304341143400_","doi-asserted-by":"publisher","DOI":"10.1186\/s42358-021-00166-8.","article-title":"Hematopoietic stem cell transplantation for systemic sclerosis: Brazilian experience","volume":"61","author":"Henrique-Neto","year":"2021","journal-title":"Adv Rheumatol"},{"key":"2023030304341143400_","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1046\/j.1365-2141.2002.03895.x","article-title":"Autologous bone marrow transplantation in the treatment of refractory systemic sclerosis: early results from a French multicentre phase I\u2013II study","volume":"119","author":"Farge","year":"2002","journal-title":"Br J Haematol"},{"key":"2023030304341143400_","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1182\/blood-2007-02-072389","article-title":"High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study","volume":"110","author":"Nash","year":"2007","journal-title":"Blood"},{"key":"2023030304341143400_","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/sj.bmt.1705782","article-title":"Autologous non-myeloablative hematopoietic stem cell transplantation in patients with systemic sclerosis","volume":"40","author":"Oyama","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"2023030304341143400_","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-019-1823-0","article-title":"CD34-selected versus unmanipulated autologous haematopoietic stem cell transplantation in the treatment of severe systemic sclerosis: a post hoc analysis of a phase I\/II clinical trial conducted in Japan","volume":"21","author":"Ayano","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2023030304341143400_","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1136\/ard.2007.071464","article-title":"Long-term follow-up results after autologous haematopoietic stem cell transplantation for severe systemic sclerosis","volume":"67","author":"Vonk","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"2023030304341143400_","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1080\/14397595.2017.1416920","article-title":"Autologous haematopoietic stem cell transplantation for Japanese patients with systemic sclerosis: long-term follow-up on a phase II trial and treatment-related fatal cardiomyopathy","volume":"28","author":"Nakamura","year":"2018","journal-title":"Mod Rheumatol"},{"key":"2023030304341143400_","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3324\/haematol.2019.230128","article-title":"Autologous stem cell transplantation for progressive systemic sclerosis: a prospective non-interventional study from the European Society for Blood and Marrow Transplantation Autoimmune Disease Working Party","volume":"106","author":"Henes","year":"2021","journal-title":"Haematologica"},{"key":"2023030304341143400_","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1182\/bloodadvances.2017011072","article-title":"Immune rebound associates with a favorable clinical response to autologous HSCT in systemic sclerosis patients","volume":"2","author":"Arruda","year":"2018","journal-title":"Blood Adv"},{"key":"2023030304341143400_","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1136\/ard.2009.127621","article-title":"Skin thickness progression rate: a predictor of mortality and early internal organ involvement in diffuse scleroderma","volume":"70","author":"Domsic","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2023030304341143400_","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.semarthrit.2017.03.020","article-title":"Cardiovascular magnetic resonance in systemic sclerosis: \u201cpearls and pitfalls\u201d","volume":"47","author":"Mavrogeni","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"2023030304341143400_","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1038\/bmt.2017.56","article-title":"Cardiopulmonary assessment of patients with systemic sclerosis for hematopoietic stem cell transplantation: recommendations from the European Society for Blood and Marrow Transplantation Autoimmune Diseases Working Party and collaborating partners","volume":"52","author":"Farge","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"2023030304341143400_","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/bmt.2011.185","article-title":"Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation","volume":"47","author":"Snowden","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"2023030304341143400_","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41409-021-01492-7","article-title":"Combining systemic and locally applied cellular therapies for the treatment of systemic sclerosis","volume":"57","author":"Velier","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"2023030304341143400_","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3109\/s10165-010-0274-x","article-title":"Therapeutic angiogenesis in patients with systemic sclerosis by autologous transplantation of bone-marrow-derived cells","volume":"20","author":"Ishigatsubo","year":"2010","journal-title":"Mod Rheumatol"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roac026\/43291658\/roac026.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/33\/2\/330\/49400500\/roac026.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/33\/2\/330\/49400500\/roac026.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T20:20:41Z","timestamp":1700338841000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/33\/2\/330\/6548062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,12]]},"references-count":53,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,3,12]]},"published-print":{"date-parts":[[2023,3,2]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roac026","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,3,1]]},"published":{"date-parts":[[2022,3,12]]}}}